Lipella Current Deferred Revenue vs Other Current Liab Analysis

LIPO Stock

2.76 0.06 2.22%

Lipella Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Lipella Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lipella Pharmaceuticals is a good investment. Please check the relationship between Lipella Pharmaceuticals Current Deferred Revenue and its Other Current Liab accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipella Pharmaceuticals Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

Current Deferred Revenue vs Other Current Liab

Current Deferred Revenue vs Other Current Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lipella Pharmaceuticals Current Deferred Revenue account and Other Current Liab. At this time, the significance of the direction appears to have weak relationship.

The correlation between Lipella Pharmaceuticals' Current Deferred Revenue and Other Current Liab is 0.35. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Lipella Pharmaceuticals Common, assuming nothing else is changed. The correlation between historical values of Lipella Pharmaceuticals' Current Deferred Revenue and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Lipella Pharmaceuticals Common are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Current Deferred Revenue i.e., Lipella Pharmaceuticals' Current Deferred Revenue and Other Current Liab go up and down completely randomly.

Correlation Coefficient

0.35

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Other Current Liab

Most indicators from Lipella Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lipella Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipella Pharmaceuticals Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

At this time, Lipella Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 17th of December 2024, Sales General And Administrative To Revenue is likely to grow to 5.04, while Issuance Of Capital Stock is likely to drop 0.00.

	2021	2022	2023	2024 (projected)
Interest Expense	6.8K	9.6K	10.8K	9.6K
Depreciation And Amortization	1.9M	2.6M	1.7K	1.6K

Interest Expense Depreciation And Amortization

Lipella Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant And Equipment Net	Current Deferred Revenue	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt
Total Assets		0.68	0.71	0.94	1.0	0.86	0.89	-0.98	-0.78	0.91	1.0	1.0	0.01	0.49	0.09	0.92	0.89	0.93	1.0	0.88	0.4	-0.93	0.88	-0.93	0.73	-0.42
Short Long Term Debt Total	0.68		0.37	0.69	0.64	0.57	0.39	-0.56	-0.21	0.57	0.64	0.65	0.33	-0.02	0.71	0.69	0.36	0.82	0.66	0.79	0.4	-0.43	0.51	-0.43	0.16	0.09
Other Current Liab	0.71	0.37		0.82	0.7	0.31	0.56	-0.71	-0.42	0.91	0.73	0.7	0.03	0.19	-0.38	0.83	0.6	0.68	0.73	0.82	-0.32	-0.54	0.35	-0.54	0.37	-0.16
Total Current Liabilities	0.94	0.69	0.82		0.92	0.65	0.75	-0.91	-0.58	0.98	0.93	0.93	0.26	0.33	0.03	1.0	0.72	0.97	0.95	0.96	0.26	-0.79	0.71	-0.79	0.52	-0.25
Total Stockholder Equity	1.0	0.64	0.7	0.92		0.88	0.91	-0.99	-0.81	0.89	1.0	1.0	-0.04	0.51	0.05	0.9	0.92	0.9	1.0	0.85	0.4	-0.94	0.9	-0.94	0.76	-0.45
Other Liab	0.86	0.57	0.31	0.65	0.88		0.88	-0.85	-0.85	0.58	0.86	0.87	-0.26	0.58	0.26	0.6	0.9	0.7	0.85	0.57	0.63	-0.91	0.96	-0.91	0.83	-0.54
Net Tangible Assets	0.89	0.39	0.56	0.75	0.91	0.88		-0.95	-0.97	0.73	0.9	0.9	-0.35	0.82	-0.1	0.71	0.92	0.74	0.89	0.68	0.42	-0.99	0.85	-0.99	0.96	-0.78
Net Debt	-0.98	-0.56	-0.71	-0.91	-0.99	-0.85	-0.95		0.86	-0.9	-0.99	-0.99	0.1	-0.62	0.05	-0.89	-0.92	-0.89	-0.98	-0.84	-0.37	0.97	-0.87	0.97	-0.82	0.56
Retained Earnings	-0.78	-0.21	-0.42	-0.58	-0.81	-0.85	-0.97	0.86		-0.58	-0.79	-0.79	0.51	-0.88	0.18	-0.54	-0.91	-0.56	-0.77	-0.49	-0.41	0.95	-0.81	0.95	-1.0	0.86
Accounts Payable	0.91	0.57	0.91	0.98	0.89	0.58	0.73	-0.9	-0.58		0.91	0.9	0.19	0.31	-0.16	0.98	0.75	0.9	0.92	0.93	0.09	-0.76	0.66	-0.76	0.52	-0.25
Cash	1.0	0.64	0.73	0.93	1.0	0.86	0.9	-0.99	-0.79	0.91		1.0	-0.03	0.49	0.03	0.91	0.91	0.91	1.0	0.87	0.36	-0.93	0.88	-0.93	0.75	-0.44
Cash And Short Term Investments	1.0	0.65	0.7	0.93	1.0	0.87	0.9	-0.99	-0.79	0.9	1.0		-0.01	0.5	0.06	0.91	0.91	0.91	1.0	0.86	0.41	-0.94	0.9	-0.94	0.75	-0.44
Net Receivables	0.01	0.33	0.03	0.26	-0.04	-0.26	-0.35	0.1	0.51	0.19	-0.03	-0.01		-0.55	0.29	0.3	-0.34	0.28	0.02	0.21	0.21	0.23	-0.06	0.23	-0.55	0.62
Common Stock Shares Outstanding	0.49	-0.02	0.19	0.33	0.51	0.58	0.82	-0.62	-0.88	0.31	0.49	0.5	-0.55		-0.23	0.29	0.6	0.35	0.48	0.28	0.39	-0.75	0.51	-0.75	0.91	-0.99
Non Current Liabilities Total	0.09	0.71	-0.38	0.03	0.05	0.26	-0.1	0.05	0.18	-0.16	0.03	0.06	0.29	-0.23		0.02	-0.15	0.25	0.05	0.14	0.54	0.06	0.15	0.06	-0.2	0.27
Other Current Assets	0.92	0.69	0.83	1.0	0.9	0.6	0.71	-0.89	-0.54	0.98	0.91	0.91	0.3	0.29	0.02		0.69	0.96	0.93	0.96	0.24	-0.75	0.68	-0.75	0.48	-0.21
Other Stockholder Equity	0.89	0.36	0.6	0.72	0.92	0.9	0.92	-0.92	-0.91	0.75	0.91	0.91	-0.34	0.6	-0.15	0.69		0.67	0.9	0.62	0.31	-0.94	0.9	-0.94	0.87	-0.57
Total Liab	0.93	0.82	0.68	0.97	0.9	0.7	0.74	-0.89	-0.56	0.9	0.91	0.91	0.28	0.35	0.25	0.96	0.67		0.93	0.96	0.42	-0.78	0.73	-0.78	0.51	-0.27
Total Current Assets	1.0	0.66	0.73	0.95	1.0	0.85	0.89	-0.98	-0.77	0.92	1.0	1.0	0.02	0.48	0.05	0.93	0.9	0.93		0.88	0.38	-0.92	0.88	-0.92	0.72	-0.42
Short Term Debt	0.88	0.79	0.82	0.96	0.85	0.57	0.68	-0.84	-0.49	0.93	0.87	0.86	0.21	0.28	0.14	0.96	0.62	0.96	0.88		0.15	-0.69	0.57	-0.69	0.44	-0.22
Common Stock	0.4	0.4	-0.32	0.26	0.4	0.63	0.42	-0.37	-0.41	0.09	0.36	0.41	0.21	0.39	0.54	0.24	0.31	0.42	0.38	0.15		-0.5	0.67	-0.5	0.41	-0.32
Property Plant And Equipment Net	-0.93	-0.43	-0.54	-0.79	-0.94	-0.91	-0.99	0.97	0.95	-0.76	-0.93	-0.94	0.23	-0.75	0.06	-0.75	-0.94	-0.78	-0.92	-0.69	-0.5		-0.91	1.0	-0.92	0.7
Current Deferred Revenue	0.88	0.51	0.35	0.71	0.9	0.96	0.85	-0.87	-0.81	0.66	0.88	0.9	-0.06	0.51	0.15	0.68	0.9	0.73	0.88	0.57	0.67	-0.91		-0.91	0.77	-0.45
Non Current Assets Total	-0.93	-0.43	-0.54	-0.79	-0.94	-0.91	-0.99	0.97	0.95	-0.76	-0.93	-0.94	0.23	-0.75	0.06	-0.75	-0.94	-0.78	-0.92	-0.69	-0.5	1.0	-0.91		-0.92	0.7
Non Currrent Assets Other	0.73	0.16	0.37	0.52	0.76	0.83	0.96	-0.82	-1.0	0.52	0.75	0.75	-0.55	0.91	-0.2	0.48	0.87	0.51	0.72	0.44	0.41	-0.92	0.77	-0.92		-0.89
Long Term Debt	-0.42	0.09	-0.16	-0.25	-0.45	-0.54	-0.78	0.56	0.86	-0.25	-0.44	-0.44	0.62	-0.99	0.27	-0.21	-0.57	-0.27	-0.42	-0.22	-0.32	0.7	-0.45	0.7	-0.89

Click cells to compare fundamentals

Lipella Pharmaceuticals Account Relationship Matchups

Pair Trading with Lipella Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipella Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipella Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Lipella Stock

0.66	BMY	Bristol Myers Squibb	Pair Corr
0.58	GILD	Gilead Sciences	Pair Corr
0.43	DYAI	Dyadic International	Pair Corr
0.43	ESPR	Esperion Therapeutics Buyout Trend	Pair Corr

The ability to find closely correlated positions to Lipella Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipella Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipella Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipella Pharmaceuticals Common to buy it.

The correlation of Lipella Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipella Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipella Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Lipella Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Lipella Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipella Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipella Pharmaceuticals Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipella Pharmaceuticals Common Stock:

How To Invest In Lipella

Details

Is Lipella Stock a good investment?

Details

What is Lipella Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipella Pharmaceuticals Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipella Pharmaceuticals. If investors know Lipella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipella Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.88)

Revenue Per Share

0.592

Quarterly Revenue Growth

0.279

Return On Assets

(0.94)

Return On Equity

(1.72)

The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lipella Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipella Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipella Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lipella Current Deferred Revenue vs Other Current Liab Analysis

Current Deferred Revenue vs Other Current Liab

Current Deferred Revenue vs Other Current Liab Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Other Current Liab

Lipella Pharmaceuticals fundamental ratios Correlations

Lipella Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pair Trading with Lipella Pharmaceuticals

Moving against Lipella Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Other Current Assets	+ 1.0	Total Current Liabilities
Cash	+ 1.0	Total Stockholder Equity

Non Currrent Assets Other	- 1.0	Retained Earnings
Long Term Debt	- 0.99	Common Stock Shares Outstanding
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Non Current Assets Total	- 0.99	Net Tangible Assets
Property Plant And Equipment Net	- 0.99	Net Tangible Assets